MCM
CTSO icon

Marathon Capital Management’s Cytosorbents Corp CTSO Stock Holding History

Marathon Capital Management’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.74K Hold
10,000
– – ﹤0.01% 187
2026
Q1 		$5.66K Buy
+10,000
New +$6.83K ﹤0.01% 171

Other funds holding CTSO

AC
Avenir Corporation Alexandria, Virginia $821M AUM 4.23% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $814M AUM 32.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Marathon Capital Management's CTSO Position: Q2 2026 in Review

Marathon Capital Management held its Cytosorbents Corp (CTSO) position steady in Q2 2026 at 10,000 shares worth $3.74K. The position accounts for ﹤0.01% of the portfolio, ranked #187.

Marathon Capital Management first reported a position in CTSO in Q1 2026 and has held it in 2 quarters since. The position peaked at $5.66K in Q1 2026. 51 funds tracked by Wall St. Rank hold CTSO as of Q2 2026.

  • Marathon Capital Management held 10,000 shares of Cytosorbents Corp worth $3.74K as of Q2 2026.
  • Marathon Capital Management left its Cytosorbents Corp share count unchanged in Q2 2026.
  • Cytosorbents Corp made up ﹤0.01% of Marathon Capital Management's portfolio in Q2 2026, its #187 holding.
  • Marathon Capital Management first reported a position in Cytosorbents Corp in Q1 2026 and has held it in 2 quarters since.
  • Marathon Capital Management's Cytosorbents Corp position peaked at $5.66K in Q1 2026.
  • 51 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2026.

Based on Marathon Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.